Innovative Treatment Platform Xoft's Electronic Brachytherapy System offers a cutting-edge, isotope-free radiation solution suitable for a wide range of cancers, including skin, breast, brain, and gynecological tumors, providing a versatile option for oncology clinics seeking advanced, minimally invasive therapies.

Market Expansion Potential With its FDA-cleared technology that can be used in virtually any clinical setting without the need for shielded environments, Xoft presents opportunities for hospitals and outpatient clinics to expand their cancer treatment offerings with portable, easy-to-integrate equipment.

Strategic Acquisition Movement The recent acquisition of Xoft by Elekta for approximately $5.5 million indicates significant industry interest and validates the company's technology, creating potential entry points for partners and customers to leverage a proven, innovative solution in their treatment protocols.

Growth and Revenue Outlook Xoft's revenue range of $10 million to $25 million, combined with a relatively small team, suggests a scalable business model with opportunity for growth through expanded adoption in medical centers and increased clinical studies.

Technology and Data Infrastructure Utilizing advanced tech stacks such as Amazon CloudFront, HTTP/3, and other web technologies, Xoft maintains modern infrastructure that supports seamless deployment, updates, and customer engagement, facilitating scalable sales and support operations.